ALK and adenocarcinoma: No significant associations of these eight target gene alterations were observed with subtypes of invasive adenocarcinoma or nodule types, other than the mutation rate of ALK fusions was higher in solid-predominant adenocarcinoma patients than that of acinar or lepidic-predominant adenocarcinoma patients (23.81% vs. 3.13%, 23.81% vs. 0.00%, P = 0.002).